Amgen

Last updated
Amgen Inc.
FormerlyApplied Molecular Genetics (1980–1983)
Company type Public
ISIN US0311621009
Industry Biotechnology
FoundedApril 8, 1980;43 years ago (1980-04-08)
Headquarters Thousand Oaks, California, U.S.
Key people
Robert A. Bradway (chairman, president & CEO)
Products
RevenueIncrease2.svg US$28.19 billion (2023)
Decrease2.svg US$7.897 billion (2023)
Increase2.svg US$6.717 billion (2023)
Total assets Increase2.svg US$97.15 billion (2023)
Total equity Increase2.svg US$6.232 billion (2023)
Number of employees
c.26,700 (2023)
Website amgen.com
Footnotes /references
[1] [2]

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, Amgen's Thousand Oaks staff in 2022 numbered approximately 5,000 [5] (8.5% of total city employment) [6] and included hundreds of scientists, making Amgen the largest employer in Ventura County. [7] [8] As of 2022, Amgen has approximately 24,000 staff in total. [9]

Contents

In 2019, the company's largest selling products were Enbrel (etanercept), [10] a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases, and Neulasta (pegfilgrastim), an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy. [11] Other marketed products include Evenity (romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib).

History

AMGen corporate logo, 1983 AMGenelogo.jpg
AMGen corporate logo, 1983
Argentine president Mauricio Macri meets with heads of Amgen, in 2018. Macri Amgen.jpg
Argentine president Mauricio Macri meets with heads of Amgen, in 2018.

Amgen was established in Thousand Oaks in 1980. [12] [7] The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics, which became the official name of the company in 1983 (three years after incorporation and coincident with its initial public offering). The company's first chief executive officer, from 1980, was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988, [13] followed by Kevin W. Sharer in 2000. [14] Robert A. Bradway became Amgen's president and chief executive officer in May 2012 following Sharer's retirement. [15] Amgen sponsored the Tour of California from 2011 to 2017. [16]

Timeline

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
  • Amgen(Founded 1983 as Applied Molecular Genetics)
    • Synergen Inc (Acq 1994)
    • Kinetix Pharmaceuticals Inc (Acq 2000)
    • Immunex Corporation (Acq 2002)
    • Tularik Inc (Acq 2004)
    • Abgenix Inc (Acq 2006)
    • Avidia Inc (Acq 2006)
    • Alantos Pharmaceuticals (Acq 2007)
    • Ilypsa Inc (Acq 2007)
    • BioVex Group Inc (Acq 2011)
    • Micromet Inc (Acq 2012)
    • Mustafa Nevzat İlaç (Acq 2012)
    • KAI Pharmaceuticals (Acq 2012)
    • deCODE genetics (Acq 2012)
    • Onyx Pharmaceuticals (Acq 2013)
    • NextCODE genetics (Spun off 2013)
    • Dezima Pharma (Acq 2015)
    • Catherex (Acq 2015)
    • Nuevolution AB (Acq 2019)
    • Otezla (apremilast) (Acq 2019) [138]
    • Five Prime Therapeutics (Acq 2021) [139]
    • Rodeo Therapeutics Corporation (Acq 2021) [140]
    • Teneobio (Acq 2021)
    • ChemoCentryx (Acq 2022) [141]
    • Horizon Therapeutics (Acq 2023)
      • Vidara Therapeutics International (Acq 2014)
      • Hyperion Therapeutics (Acq 2015)
      • Crealta Holdings (Acq 2015)
      • Raptor Pharmaceutical (Acq 2016)
      • River Vision Development Corp. (Acq 2017)
      • Viela Bio Inc (Acq 2021)

Products

Amgen's approved drugs or therapeutic biologicals include:

Products developed and then sold off

Pipeline and clinical trials

As of August 2022, Amgen had 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. [146]

In September 2019, FDA granted fast track designation to sotorasib for the treatment of metastatic non-small-cell lung carcinoma (NSCLC) with the KRAS G12C mutation. [147]

In August 2020, Amgen, Takeda, and AbbVie, as part of a COVID-19 research and development (R&D) alliance, announced the first patients enrolled in the I-SPY COVID clinical trial. The trial evaluated the efficacy of Otezla and two other medicines in severely ill, hospitalized COVID-19 patients who required high-flow oxygen. [148]

In October 2020, Amgen announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib in 126 patients with KRAS G12C-mutant advanced NSCLC who had failed three or fewer prior lines of anti-cancer therapies (including immunotherapy and/or chemotherapy). [149] Amgen, the Global Coalition for Adaptive Research, and Eisai Co., Ltd. also announced enrollment of the first patient in a study testing multiple interventions for the treatment of patients hospitalized with COVID-19. [150] [151]

In November 2020, Amgen, Takeda, and UCB, as part of the COVID R&D alliance, announced the first patient enrolled in another trial evaluating Otezla and two other drugs as treatments for COVID-19. [152] Amgen also announced that it would terminate its collaboration with Cytokinetics and transition the development and commercialization rights for omecamtiv mecarbil and AMG 594. [153] Amgen and AstraZeneca announced positive topline results from a Phase 3 trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations in patients with severe asthma. [154]

In December 2020, the FDA granted breakthrough therapy designation to sotorasib for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation. [155]

In May 2021, sotorasib received accelerated approval from FDA for treatment of adult patients with NSCLC whose tumors have a KRAS G12C mutation and who have received at least one prior systemic therapy; this was the first approved targeted therapy for tumors with any KRAS mutation. [156] Similar approvals for sotorasib in NSCLC followed in January 2022 in Europe [157] and Japan. [158]

In September 2022, data from a late-stage study showed the company's cancer pill Lumakras beating out chemotherapy. This was the first approved drug in the set of treatments that target KRAS, among the most common generic mutations found in cancers but one where researchers have struggled for years to design drugs to treat. The drug was approved in 2021 with a list price of $17,900 per month. [159]

Carbon footprint

Amgen reported Total CO2e emissions (Direct + Indirect) for the twelve months ending 31 December 2020 at 243 Kt (-6 /-2.4% y-o-y) [160] and aims to reach net zero emissions by 2027. [161]

Amgen's annual Total CO2e Emissions - Location-Based Scope 1 + Scope 2 (in kilotonnes) [160]
Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
354369292279264249243

Public-private engagement

Amgen engages with the public and private sectors in a variety of settings including to promote research and development, academic funding, event sponsorship, philanthropy, and political lobbying.

Academia

Events and conferences

Health care

Media

Medical societies

Political lobbying

Professional associations

Research and development

See also

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc (AZ) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">Bristol Myers Squibb</span> American pharmaceutical company

The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb (BMS), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Eli Lilly and Company</span> American pharmaceutical company

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and a Union Army veteran of the American Civil War.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.

<span class="mw-page-title-main">Sunovion</span> Pharmaceutical company

On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.

Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.

<span class="mw-page-title-main">Merck & Co.</span> American multinational pharmaceutical company

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.

Onyx Pharmaceuticals Inc. has been a biopharmaceutical company headquartered in South San Francisco, California. The company developed and marketed medicines for the treatment of cancer. Onyx was founded in 1992 by Kevin J. Kinsella and Frank McCormick Ph.D., FRS. McCormick served as the chief scientific officer until 1998, while Kinsella was the firm's chairman. In 2009, the company acquired Proteolix, Inc., a private biotechnology company, for $276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" through an industry survey. Onyx president and chief executive officer (CEO) Tony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, at the end of August 2013, Amgen announced it was acquiring Onyx in an agreed $10.4 billion deal.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company’s seat in Forbes Global 2000 was 74. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Jazz Pharmaceuticals plc is an American biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals

K-Ras(G12C) inhibitor 6 is an irreversible inhibitor of oncogenic K-Ras(G12C), subverting the native nucleotide preference to favour GDP over GTP. Its family of inhibitors allosterically control GTP affinity and effector interactions by fitting inside a "pocket", or binding site, of mutant K-Ras. It is the most frequently mutated oncogene.

<span class="mw-page-title-main">Sotorasib</span> Chemical compound

Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer. It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer. Sotorasib is an inhibitor of the RAS GTPase family.

BeiGene is a global biotechnology company that specializes in the development of drugs for cancer treatment. Founded in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in Asia, North America, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor.

References

  1. "About Amgen Fact Sheet". amgen.com. Retrieved 9 March 2020.
  2. "US SEC: 2023 Form 10-K Amgen Inc". U.S. Securities and Exchange Commission. February 14, 2024.
  3. Amgen History official site page accessed January 2, 2016
  4. Ronald Vogel. Pharmaceutical Economics and Public Policy. CRC Press, 2007. ISBN   9781439801345. P. 208
  5. Biasotti, Tony (9 April 2022). "In Thousand Oaks, biotech execs discuss industry's 'rising tide,' lament area's lack of housing". Pacific Coast Business Times. Retrieved 19 September 2022.
  6. "Annual Comprehensive Financial Report". City of Thousand Oaks, California. 30 June 2021. p. 156. Retrieved 19 September 2022.
  7. 1 2 Baker, Pam (2002). Thousand Oaks Westlake Village: A Contemporary Portrait. Community Communications, Inc., p. 37. ISBN   978-1581920611.
  8. "Biotech giant Amgen has big plans for new plant". Moorpark Acorn. 16 February 2018.
  9. Talhelm, Matt (7 March 2022). "Amgen to offer workers an average salary of $119,510 at new facility". WRAL TechWire. Retrieved 20 September 2022.
  10. Blankenship, Kyle (27 July 2020). "The top 20 drugs by global sales in 2019". Fierce Pharma. Retrieved 12 July 2022.
  11. Hagen, Tony (4 February 2021). "Amgen Profits Get a Ride on Biosimilar Growth". The Center For Biosimilars. Retrieved 12 July 2022.
  12. Bidwell, Carol A. (1989). The Conejo Valley: Old and New Frontiers. Windsor Publications. p. 128. ISBN   978-0897812993.
  13. "Amgen, Form 10-K, Annual Report, Filing Date Mar 24, 1998". secdatabase.com. Retrieved Jan 8, 2013.
  14. "Amgen, Form 10-K405, Filing Date Mar 7, 2000". secdatabase.com. Retrieved Jan 8, 2013.
  15. "Amgen, Form 8-K, Current Report, Filing Date May 24, 2012". secdatabase.com. Retrieved Jan 8, 2013.
  16. "Amgen Tour of California". amgentourofcalifornia.com. Archived from the original on 2020-02-04. Retrieved 2020-02-07.
  17. 1 2 Walsh, Robin (27 October 2010). "A history of: Amgen". pharmaphorum.com. Retrieved 10 August 2022.
  18. "Amgen—A biotechnology success story | From drug development to the mass market". Archived from the original on 2014-10-24. Retrieved 2016-09-12.
  19. "Small Company Initial Public Offerings: June 1983". Inc.com. 1 September 1983. Retrieved 10 August 2022.
  20. Ward, Nicholas (21 April 2019). "Amgen: This Beaten Down Blue Chip Is Priced To Own". TheStreet. Retrieved 10 August 2022.
  21. Timmerman, Luke (13 May 2002). "Shrewd science: Biotech giant Amgen's success reflects its savvy corporate style". The Seattle Times. Retrieved 10 August 2022.
  22. Bate, James (2 June 1989). "Biotech Detective Scores Coup : Amgen scientist spent years searching for the key to producing EPO". Los Angeles Times. Retrieved 10 August 2022.
  23. 1 2 Kim, Rachel (2019). Economics and management in the biopharmaceutical industry in the USA : evolution and strategic change. London: Routledge. pp. 2002–2003. ISBN   9781351012690 . Retrieved 10 August 2022.
  24. "Kirin and Amgen Hormone Venture". The New York Times. Reuters. 15 June 1984. Retrieved 10 August 2022.
  25. Murphy, Barbara (20 May 1997). "Souza to Run Research at Biotech King Amgen". Los Angeles Times. Retrieved 10 August 2022.
  26. Bendall, Linda J.; Bradstock, Kenneth F. (August 2014). "G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent". Cytokine & Growth Factor Reviews. 25 (4): 355–367. doi: 10.1016/j.cytogfr.2014.07.011 . PMID   25131807.
  27. "Gordon M. Binder, chief executive of Amgen..." Los Angeles Times. 17 October 1995. Retrieved 10 August 2022.
  28. 1 2 "Drugs@FDA: FDA Approved Drug Products".
  29. "Amgen and its erythropoietin drugs". The Washington Post. 19 July 2012. Retrieved 20 September 2022.
  30. "Drugs@FDA: FDA Approved Drug Products".
  31. Lyman GH, Kuderer NM, Djulbegovic B (April 2002). "Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis". Am. J. Med. 112 (5): 406–11. doi:10.1016/s0002-9343(02)01036-7. PMID   11904116.
  32. Spencer, Dina (26 Sep 2019). "5 Top Pharma Manufacturers in Puerto Rico". PharmaBoardroom. Retrieved 10 August 2022.
  33. Nathans, Aaron (16 September 1994). "Amgen, Phone Entrepreneur Win Medal of Technology". Los Angeles Times. Retrieved 10 August 2022.
  34. "A Biotech Wonder Grows Up". Forbes. 3 Sep 2001. Retrieved 10 August 2022.
  35. Chen YF, Jobanputra P, Barton P, et al. (November 2006). "A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness". Health Technol Assess. 10 (42): iii–iv, xi–xiii, 1–229. doi: 10.3310/hta10420 . PMID   17049139.
  36. Morgan CL, Emery P, Porter D, et al. (January 2014). "Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data". Rheumatology (Oxford). 53 (1): 186–94. doi: 10.1093/rheumatology/ket333 . PMID   24140761.
  37. Hemp, Paul (1 July 2004). "A Time for Growth: An Interview with Amgen CEO Kevin Sharer". Harvard Business Review. Retrieved 10 August 2022.
  38. Pollack, Andrew (19 September 2001). "F.D.A. Approves New Version of Amgen Drug". The New York Times. Retrieved 10 August 2022.
  39. "FDA approves Amgen's new-generation filgrastim product, Neulasta". www.thepharmaletter.com. 2 Nov 2002. Retrieved 10 August 2022.
  40. Pollack, Andrew (17 July 2002). "Amgen Reports Its Takeover Of Immunex". The New York Times. Retrieved 10 August 2022.
  41. "New FDA Approvals". Relias Media. 1 May 2004. Retrieved 10 August 2022.
  42. "Drug Approval Package: Sensipar (Cinacalcet HCI) NDA #021688". U.S. Food and Drug Administration. Retrieved 10 August 2022.
  43. Gellene, Denise (30 March 2004). "Amgen to Buy Rival Tularik". Los Angeles Times. Retrieved 10 August 2022.
  44. "Amgen buys remaining 79% of Tularik for $1.3B to boost R&D pipeline". The Pharma Letter. 4 April 2004. Retrieved 10 August 2022.
  45. Pollack, Andrew (15 December 2005). "Amgen to Buy Abgenix, Getting Complete Control of New Colon Cancer Drug". The New York Times. Retrieved 10 August 2022.
  46. Giusti, Ruthann M.; Shastri, Kaushikkumar A.; Cohen, Martin H.; Keegan, Patricia; Pazdur, Richard (May 2007). "FDA drug approval summary: panitumumab (Vectibix)". The Oncologist. 12 (5): 577–583. doi:10.1634/theoncologist.12-5-577. ISSN   1083-7159. PMID   17522246. S2CID   9376408 . Retrieved 10 August 2022.
  47. Heavey, Susan (22 August 2008). "U.S. FDA approves Amgen's blood platelet booster". Reuters. Retrieved 10 August 2022.
  48. Jamali, Faranak; Lemery, Steven; Ayalew, Kassa; Robottom, Suzanne; Robie-Suh, Kathy; Rieves, Dwaine; Pazdur, Richard (July 2009). "Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura". Oncology (Williston Park, N.Y.). 23 (8): 704–709. ISSN   0890-9091. PMID   19711585 . Retrieved 10 August 2022.
  49. "Drugs@FDA: FDA Approved Drug Products".
  50. "www.accessdata.fda.gov" (PDF).
  51. "FDA approves Xgeva to help prevent cancer-related bone injury". Food and Drug Administration .
  52. "Amgen to buy Pfizer plant". The Irish Times. 11 March 2011. Retrieved 10 August 2022.
  53. Timmerman, Luke (24 January 2011). "Xconomy: Amgen to Acquire BioVex for Up To $1B, to Obtain Cancer-Killing Virus Therapy". Xconomy. Retrieved 10 August 2022.
  54. Dangi-Garimella, Surabhi (28 October 2015). "Cost Questions Will Follow the Approval of Amgen's Oncolytic Viral Treatment, Imlygic". AJMC. Retrieved 10 August 2022.
  55. Pollack, Andrew (20 December 2011). "Amgen Plans to Team Up With Watson on Generics". The New York Times. Retrieved 10 August 2022.
  56. Terhune, Chad (18 December 2012). "Amgen pleads guilty to improper marketing of anemia drug Aranesp". Los Angeles Times. Retrieved 2 February 2013.
  57. Husten, Larry. "Amgen Pleads Guilty To Misbranding Anemia Drug Aranesp". Forbes. Retrieved 2 February 2013.
  58. "Article > Amgen's Aranesp fails in heart trial, Singapore plant planned". 17 January 2013.
  59. Lipton, Eric (19 January 2013). "Fiscal Footnote: Big Senate Gift to Drug Maker". The New York Times . Retrieved 2 February 2013.
  60. "Jon Entine: New York Times Mum After Congressional Budget Office Rebukes Bungled Amgen/Medicare Investigation". Huffington Post. 26 February 2013.
  61. "CBO analysis shows keeping oral drugs out of ESRD bundle could save money | Nephrology News & Issues". Archived from the original on 2013-06-05.
  62. "Amgen to buy Micromet for $1.2 billion". Reuters. 26 January 2012. Retrieved 10 August 2022.
  63. "Amgen appoints CEO Robert Bradway to chair of board". PMLive. 17 December 2012. Retrieved 10 August 2022.
  64. Writer, GEN Staff (25 April 2012). "Amgen Ponies Up $700M for Turkey's Mustafa Nevzat". GEN - Genetic Engineering and Biotechnology News. Retrieved 10 August 2022.
  65. "Amgen to Pick Up Peptide Drug Firm KAI Pharmaceuticals for $315M". GEN - Genetic Engineering and Biotechnology News. 10 April 2012.
  66. Taylor, Phil (8 February 2017). "Amgen's chronic kidney disease drug Parsabiv cleared in US". PMLive. Retrieved 11 August 2022.
  67. "Amgen Buys deCODE Genetics for $415M". GEN - Genetic Engineering and Biotechnology News. 10 December 2012.
  68. Becker, Zoey (27 June 2022). "Amgen partners with Fosun to bring Otezla, Parsabiv to patients in China". Fierce Pharma.
  69. Philippidis, Alex (1 November 2019). "Amgen Expands China Presence, Cancer R&D with $2.7B BeiGene Collaboration". GEN - Genetic Engineering and Biotechnology News. Retrieved 11 August 2022.
  70. Wright, Rob (27 Aug 2018). "Amgen's Acquisition Of Onyx Pharmaceuticals — Through The Eyes Of Tony Coles". Life Science Leader. Retrieved 11 August 2022.
  71. "GEN - News Highlights:Amgen Halts Rilotumumab Trials in Advanced Gastric Cancer". GEN. 24 November 2014.
  72. "GEN - News Highlights:Brodalumab's No Turkey in Phase III: Amgen and AstraZeneca". GEN.
  73. Brennan, Zachary (21 November 2014). "Amgen launches $200m biomanufacturing facility in Singapore". BioPharma-Reporter. Retrieved 11 August 2022.
  74. Przepiorka, Donna; Ko, Chia-Wen; Deisseroth, Albert; Yancey, Carolyn L.; Candau-Chacon, Reyes; Chiu, Haw-Jyh; Gehrke, Brenda J.; Gomez-Broughton, Candace; Kane, Robert C.; Kirshner, Susan; Mehrotra, Nitin; Ricks, Tiffany K.; Schmiel, Deborah; Song, Pengfei; Zhao, Ping; Zhou, Qing; Farrell, Ann T.; Pazdur, Richard (15 September 2015). "FDA Approval: Blinatumomab". Clinical Cancer Research. 21 (18): 4035–4039. doi:10.1158/1078-0432.CCR-15-0612. ISSN   1557-3265. PMID   26374073. S2CID   207687724 . Retrieved 11 August 2022.
  75. "FDA Approves Blinatumomab to Treat Rare Form of Acute Lymphoblastic Leukemia". The ASCO Post. 15 December 2014. Retrieved 11 August 2022.
  76. "GEN - News Highlights:Celimmune Licenses Amgen's AMG 714 for Celiac Disease". GEN.
  77. Kolata, Gina (27 August 2015). "F.D.A. Approves Repatha, a Second Drug for Cholesterol in a Potent New Class". The New York Times. Retrieved 11 August 2022.
  78. "For Up to $1.55B, Amgen Acquires Dezima Pharma". GEN. 16 September 2015.
  79. "Amgen bets up to $1.7B on Xencor's antibody technology". FierceBiotech. 16 September 2015.
  80. "Amgen, Xencor to Partner on Cancer Immunotherapy, Inflammation Drugs". GEN. 16 September 2015.
  81. Tontonoz, Matthew. "T-VEC is First FDA-Approved Oncolytic Virus Therapy". Cancer Research Institute. Retrieved 11 August 2022.
  82. "Amgen Buys Rights to Myeloma BiTE Immunotherapy from Boehringer Ingelheim - GEN News Highlights - GEN". September 2016.
  83. 1 2 Staton, Tracy (23 September 2016). "Amgen's Humira biosim, Amjevita, passes FDA milestone on long road to market". Fierce Pharma. Retrieved 11 August 2022.
  84. "Amgen Reports Fourth Quarter And Full Year 2017 Financial Results". www.amgen.com. Retrieved 2018-05-14.
  85. Bell, Jacob (8 February 2017). "Amgen secures FDA approval for hormone drug". BioPharma Dive. Retrieved 11 August 2022.
  86. 1 2 "FDA approves bevacizumab biosimilar Mvasi". GaBI Online. 22 September 2017. Retrieved 11 August 2022.
  87. Vuocolo, Alex (23 June 2020). "Khan Academy Founder Says $3M Grant Will Help Tackle Inequities in Virtual Education". Cheddar News. Retrieved 11 August 2022.
  88. D'Angelo, Alexa (29 October 2017). "Amgen Foundation awards Khan Academy $3 million to support development of biology". Ventura County Star. Retrieved 11 August 2022.
  89. "Fortune 500 company by revenue 2018 cial". www.fortune.com. Archived from the original on 2020-03-29. Retrieved 2019-03-18.
  90. Raedler, Lisa A. (15 April 2019). "Aimovig (Erenumab-aooe) First CGRP Receptor Antagonist Approved for the Prevention of Migraine in Adults". American Health & Drug Benefits. 12. Retrieved 11 August 2022.
  91. "Amgen's New Bio-manufacturing Plant, Rhode Island, US". Pharmaceutical Technology. 10 August 2018. Retrieved 11 August 2022.
  92. "Evenity gets first ever approval, in Japan". The Pharma Letter. 9 January 2019. Retrieved 11 August 2022.
  93. Taylor, Phil (9 January 2019). "Amgen gets first OK for Evenity in Japan as FDA panel looms". Fierce Biotech. Retrieved 11 August 2022.
  94. Liu, Angus (10 April 2019). "Amgen bone drug Evenity finally wins its FDA green light, but there's a catch". Fierce Pharma. Retrieved 11 August 2022.
  95. 1 2 "FDA Approves Amgen's Trastuzumab Biosimilar, Kanjinti". The Center For Biosimilars. 13 June 2019. Retrieved 11 August 2022.
  96. "Amgen to buy Copenhagen-based Nuevolution for $167 million". Reuters. 22 May 2019 via uk.reuters.com.
  97. "Amgen to Acquire Otezla® for $13.4 Billion in Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits".
  98. "Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion". Reuters. 26 August 2019.
  99. "Amgen acquires stake in BeiGene to grow cancer drug business to China". 31 October 2019.
  100. "CDC Foundation Active Programs October 1, 2020 – September 30, 2021". CDC Foundation . 2021-12-09. Archived from the original on 2022-01-15. Retrieved 2022-08-06.
  101. "FDA approves Avsola, fourth Remicade biosimilar". www.healio.com. 6 Dec 2019. Retrieved 11 August 2022.
  102. Kelly, Rhea (24 January 2020). "Amgen and Harvard Launch Free Online Science Ed Platform -- Campus Technology". Campus Technology. Retrieved 11 August 2022.
  103. Kahn, Natalie L.; Wang, Andy Z. (8 April 2020). "Harvard's LabXChange Provides Platform for Remote Scientific Learning During Pandemic | News | The Harvard Crimson". The Harvard Crimson. Retrieved 11 August 2022.
  104. "Amgen, AT&T, Others Announce Commitments for COVID-19 Response". Philanthropy News Digest. 25 March 2020. Retrieved 20 September 2022.
  105. "BRIEF-Amgen Establishes Wholly-Owned Affiliate In Japan". Reuters. 1 April 2020. Retrieved 11 August 2022.
  106. Liu, Angus (23 January 2020). "Amgen wades deeper into Asia with full control of an Astellas Japanese JV". Fierce Pharma. Retrieved 11 August 2022.
  107. "Amgen defeats Novartis appeal over arthritis drug Enbrel's patents". Reuters. 1 July 2020. Retrieved 11 August 2022.
  108. "Amgen Foundation awards $3 million to Khan Academy". Philanthropy News Digest. 24 July 2020. Retrieved 20 September 2022.
  109. Molina, Brett (30 July 2020). "Q&A: Khan Academy CEO Sal Khan on the new school year and virtual learning". USA Today. Retrieved 20 September 2022.
  110. Stevens, Pippa (24 August 2020). "Salesforce, Amgen and Honeywell added to Dow in major shake-up to the average". CNBC. Retrieved 11 August 2022.
  111. Blankenship, Kyle (17 September 2020). "Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails". Fierce Pharma. Retrieved 11 August 2022.
  112. Manfredi, Lucas (18 January 2021). "CEOs are driving an initiative to hire, train 1M Black workers over next 10 years". FOXBusiness. Retrieved 11 August 2022.
  113. 1 2 "FDA Approves Riabni, Third Biosimilar to Rituxan". Clinical Oncology News. 18 December 2020. Retrieved 20 September 2022.
  114. "Amgen to Acquire Five Prime Therapeutics for $1.9 Billion in Cash".
  115. "Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market". Reuters. 4 March 2021.
  116. "In Second Acquisition this Month, Amgen Buys Rodeo for $721 Million".
  117. 1 2 ASCO Post Staff (June 25, 2021). "FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC". ASCO Post. Retrieved March 4, 2022.
  118. Idrus, Amirah Al (1 June 2021). "Amgen reunites with longtime partner Kyowa Kirin in $400M dermatitis deal". Fierce Biotech. Retrieved 20 September 2022.
  119. Taylor, Nick Paul (7 October 2021). "Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D". Fierce Biotech. Retrieved 20 September 2022.
  120. "Amgen to invest $100 million in SoftBank-backed Neumora". Reuters. 7 October 2021. Retrieved 20 September 2022.
  121. "Amgen breaks ground on new biomanufacturing facility in Ohio, US". NS Healthcare. 8 November 2021. Retrieved 20 September 2022.
  122. 1 2 Dunleavy, Kevin (20 December 2021). "Amgen, AstraZeneca score FDA nod for blockbuster hopeful asthma drug Tezspire". Fierce Pharma. Retrieved 20 September 2022.
  123. "U.S. FDA approves expanded use of Amgen's psoriasis drug". Reuters. 20 December 2021. Retrieved 20 September 2022.
  124. Armstrong, Annalee (6 January 2022). "Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs". Fierce Biotech. Retrieved 23 September 2022.
  125. Philippidis, Alex (6 January 2022). "Amgen, Generate Launch Up-to-$1.9B Protein Therapeutics Collaboration". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 September 2022.
  126. Armstrong, Annalee (11 January 2022). "JPM 2022: Amgen teams up with Arrakis to destroy disease-causing RNA in $75M research deal". Fierce Biotech. Retrieved 23 September 2022.
  127. Pagliarulo, Ned (11 January 2022). "Amgen partners with Arrakis to develop drugs aimed at RNA". BioPharma Dive. Retrieved 23 September 2022.
  128. Shasteen, Hayley (3 February 2022). "Amgen and Plexium Ink $500M Targeted Protein Degradation Therapies Pact". BioSpace. Retrieved 23 September 2022.
  129. LaHucik, Kyle (3 February 2022). "Amgen enters hot protein degradation field with $500M biobucks deal with Plexium". Fierce Biotech. Retrieved 23 September 2022.
  130. Pequeño IV, Antonio (23 February 2022). "Amgen Issues 'Green Bond'". San Fernando Valley Business Journal. Retrieved 23 September 2022.
  131. Mutua, David Caleb (29 March 2022). "Amgen Mulls More Green Bonds After 'Robust Interest' in Debut". www.bloomberg.com. Retrieved 23 September 2022.
  132. Parker, Jason (7 March 2022). "Amgen expects new Holly Springs plant to be 'a permanent home'". WRAL TechWire. Retrieved 11 July 2023.
  133. Sterling, John (11 March 2022). "Amgen Breaks Ground on NC Biomanufacturing Facility". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 September 2022.
  134. Walker, Joseph (4 August 2022). "Amgen to Buy ChemoCentryx for $3.7 Billion" . The Wall Street Journal . Archived from the original on 4 August 2022.
  135. Mishra, Manas; Satija, Bhanvi (12 December 2022). "Amgen dives deeper into rare disease drugs with $27.8 BLN Horizon deal". Reuters.
  136. "Amgen completes $27.8 billion Horizon deal". Reuters. 6 October 2023.
  137. 1 2 "Amgen forges ahead with generative AI to expedite advanced therapies". Ventureburn. 2023-12-01. Retrieved 2023-12-07.
  138. Erman, Michael; Mishra, Manas (26 August 2019). "Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion". Reuters. Retrieved 23 September 2022.
  139. Adams, Ben (4 March 2021). "Prime time for Five Prime as Amgen snaps up this once-moribund biotech for $1.9B and its phoenix-from-the-flames cancer asset". Fierce Biotech. Retrieved 23 September 2022.
  140. Idrus, Amirah Al (30 March 2021). "Amgen saddles up with Rodeo for a $55M trek into regenerative medicine". Fierce Biotech. Retrieved 23 September 2022.
  141. Philippidis, Alex (5 August 2022). "Amgen to Acquire ChemoCentryx for $3.7B, Bolstering Autoimmune Portfolio". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 September 2022.
  142. Food and Drug Administration December 3, 2014 FDA Press release: Blinatumomab
  143. Jeffries, Fleur (28 March 2022). "Amgen shares new Otezla data at American Academy of Dermatology congress 2022". PMLive. Retrieved 11 August 2022.
  144. 1 2 3 Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine
  145. "Stemgen® (ancestim)". sobi.com. Archived from the original on 2013-12-30. Retrieved 2013-12-30.
  146. "Amgen Pipeline". Amgen Pipeline. Retrieved 16 August 2022.
  147. Lisa Astor (September 9, 2019). "FDA Grants AMG 510 Fast Track Designation for KRAS G12C+ NSCLC". targetedonc.com. Retrieved November 16, 2019.
  148. Liu, Angus (3 August 2020). "AbbVie, Amgen and Takeda test anti-inflammatory drugs in joint COVID-19 study". Fierce Pharma.
  149. Helwick, Caroline (1 Feb 2021). "Phase II CodeBreak 100 Validates Early Benefit for KRAS Inhibitor in NSCLC". The ASCO Post. Retrieved 16 August 2022.
  150. "Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More". Yahoo Finance. 28 Oct 2020. Retrieved 16 August 2022.
  151. Ross, Casey (10 November 2020). "Drug companies deliver a vote of confidence in adaptive trial for Covid-19". STAT. Retrieved 16 August 2022.
  152. Beasley, Deena (30 November 2020). "COVID R&D Alliance launches trial of Amgen, UCB, Takeda drugs". Reuters. Retrieved 16 August 2022.
  153. Gardner, Jonathan (23 Nov 2020). "Amgen cuts Cytokinetics loose after heart drug disappointment". BioPharma Dive. Retrieved 16 August 2022.
  154. Dembeck, Lauren (18 October 2021). "NAVIGATOR Trial Outcomes for Tezepelumab Use in Severe, Uncontrolled Asthma". Pulmonology Advisor. Retrieved 16 August 2022.
  155. Taylor, Nick Paul (8 December 2020). "Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib". Fierce Biotech. Retrieved 16 August 2022.
  156. ASCO Post Staff (June 25, 2021). "FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC". ascopost.com. Retrieved March 4, 2022.
  157. Kristi Rosa (January 10, 2022). "Sotorasib Approved in Europe for KRAS G12C–Mutated Advanced NSCLC". www.onclive.com. Retrieved March 4, 2022.
  158. Audrey Sternberg (January 20, 2022). "Sotorasib Earns Approval in Japan for KRAS G12C+ NSCLC". cancernetwork.com. Retrieved March 4, 2022.
  159. Walker, Joseph (2022-09-12). "New Cancer Drug Beats Chemotherapy in Study". The Wall Street Journal . ISSN   0099-9660 . Retrieved 2022-09-12.
  160. 1 2 "Amgen's ESG Datasheet for 2020Q4" (PDF). Alt URL
  161. "Amgen's Sustainability Report for 2020Q4" (PDF). Archived from the original (PDF) on July 17, 2021. Alt URL
  162. Simonyi, Charles; Dijkgraaf, Robbert (2013). "Report for the Academic Year 2012-2013" (PDF). Institute for Advanced Study . Archived (PDF) from the original on 2022-08-02. Retrieved 2022-08-02.
  163. "Amgen Biotech Experience (ABE-LA)". LA Promise Fund . 2022-02-23. Archived from the original on 2022-08-06. Retrieved 2022-08-06.
  164. "Donor Listing". University of Toronto . Archived from the original on 2021-04-23. Retrieved 2022-08-06.
  165. "Honor Roll of Donors" (PDF). University of Washington; Amazon Web Services . 2020. Archived (PDF) from the original on 2022-06-10. Retrieved 2022-08-05.
  166. BUKSA Strategic Conference Services (2021). "Virtual Series Sponsor Profile: Amgen". Alberta Kidney Days Virtual Series. Archived from the original on 2022-08-02. Retrieved 2022-08-02.
  167. "Compassion in kidney care: from patients to providers" (PDF). BC Renal Agency . 2013. Archived (PDF) from the original on 2022-01-08. Retrieved 2022-08-02.
  168. "Sponsors". Mentoring in IBD. 2022. Archived from the original on 2022-04-19. Retrieved 2022-08-02.
  169. "The 8th Princess Margaret Hospital Conference: Developments in Cancer Management". FDocuments India. 2020-07-17. Archived from the original on 2022-06-20. Retrieved 2022-08-05.
  170. "Recognizing your contribution". Kingston University Hospital Foundation . 2019-12-31. Archived from the original on 2022-08-03. Retrieved 2022-08-04.
  171. Fukakusa, Janice; Yamashita, Miyo. "2021 Annual Report" (PDF). Princess Margaret Cancer Centre . Archived (PDF) from the original on 2021-11-20. Retrieved 2022-08-05.
  172. "Donor List". Providence Health Care . Archived from the original on 2022-02-08. Retrieved 2022-08-05.
  173. "Our Donors". Scarborough Health Network Foundation . 2021. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  174. "2020-21 SickKids Annual Report". SickKids Foundation . 2021. Archived from the original on 2022-06-20. Retrieved 2022-08-05.
  175. "Donor List - Cumulative". Sinai Health Annual Report . 2021-03-31. Archived from the original on 2022-08-06. Retrieved 2022-08-06.
  176. 1 2 "St. Michael's Foundation 2020/21 Annual Report". FlippingBook. 2021. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  177. "Our donors - Your Impact". Sunnybrook Foundation . 2022. Archived from the original on 2022-08-06. Retrieved 2022-08-06.
  178. Hanson, Tennys; Kothari, Raj. "2020/21 Report to Our Donors". UHN Foundation . Archived from the original on 2022-05-07. Retrieved 2022-08-06.
  179. "Donor Listings". Women's College Hospital Foundation. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  180. "The Power of Philanthropy" (PDF). National Geographic Society . Archived (PDF) from the original on 2022-05-10. Retrieved 2022-08-04.
  181. "Corporate Support". American Society of Hematology . 2022. Archived from the original on 2022-06-10. Retrieved 2022-08-02.
  182. "Partners". Arthritis Society . 2022. Archived from the original on 2022-05-14. Retrieved 2022-08-02.
  183. "2019 Donors to the CSHP Foundation by Giving Level". Canadian Society of Hospital Pharmacists . Archived from the original on 2022-04-19. Retrieved 2022-08-04.
  184. "Our Partners". CSN/SCN. 2022. Archived from the original on 2022-01-08. Retrieved 2022-08-02.
  185. "Corporate Liaison Board". Endocrine Society . 2022. Archived from the original on 2022-06-10. Retrieved 2022-08-02.
  186. "Why sponsor the EURObservational Registry Programme". European Society of Cardiology . 2022. Archived from the original on 2022-06-15. Retrieved 2022-08-03.
  187. "AGM 2010: The Many Faces of Medical Women" (PDF). Federation of Medical Women in Canada . 2010. Archived (PDF) from the original on 2022-03-06. Retrieved 2022-08-03.
  188. "List of Members". Alliance for a Stronger FDA. 2022-03-04. Archived from the original on 2022-07-08. Retrieved 2022-08-02.
  189. "How We're Funded Advocacy & Support". Alliance for Aging Research . 2022. Archived from the original on 2022-07-15. Retrieved 2022-08-02.
  190. "Member Listings". BIOTECanada . 2021-12-23. Archived from the original on 2022-08-02. Retrieved 2022-08-02.
  191. Grumet, Jason (2016). "Dialogue Issue III: The Annual Report Issue 2015-2016" (PDF). Bipartisan Policy Center . Archived (PDF) from the original on 2022-07-07. Retrieved 2022-08-02.
  192. "Active Members". The Business Council . 2022. Archived from the original on 2022-07-13. Retrieved 2022-07-02.
  193. "CDC Foundation Active Programs". CDC Foundation . 2021-12-09. Archived from the original on 2022-01-15. Retrieved 2022-08-02.
  194. "Industry Network". CCRM. 2019-04-10. Archived from the original on 2022-08-02. Retrieved 2022-08-02.
  195. "Corporate Members". Council on Foreign Relations. Retrieved 2022-08-02.
  196. "Membership". European Federation of Pharmaceutical Industries and Associations . 2022. Archived from the original on 2022-07-01. Retrieved 2022-08-02.
  197. "2020 Donors". FNIH 2020 Annual Report. Archived from the original on 2022-03-16. Retrieved 2022-08-03.
  198. "Explore Our Collaborations". Global Health Progress. 2022. Archived from the original on 2022-04-03. Retrieved 2022-08-04.
  199. "Members". Health Products Stewardship Association. 2022. Archived from the original on 2022-04-27. Retrieved 2022-08-04.
  200. "Member Companies". Innovative Medicines Canada . 2021. Archived from the original on 2022-05-31. Retrieved 2022-08-04.
  201. "Companies". IFPMA. Archived from the original on 2022-07-01. Retrieved 2022-08-04.
  202. "Our Sponsors". Life Sciences British Columbia. 2021-01-06. Archived from the original on 2022-04-25. Retrieved 2022-08-04.
  203. Higgins, Connie (2020-04-28). "Amgen Foundation commits $2M to Ventura and Los Angeles Counties COVID-19 response" (PDF). Amgen. Archived (PDF) from the original on 2022-07-06. Retrieved 2022-08-04.
  204. "Our Members". National Health Council . 2022. Archived from the original on 2022-04-06. Retrieved 2022-08-05.
  205. "Current Members". Personalized Medicine Coalition . 2021. Archived from the original on 2021-08-15. Retrieved 2022-08-05.
  206. Pharmaceutique, Pharmaceutical Advertising Advisory Board / Conseil Consultatif de Publicité. "PAAB : About". www.paab.ca. Retrieved 2022-08-05.
  207. "About". Pharmaceutical Research and Manufacturers of America . Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  208. Winckler, Susan C.; Woodcock, Janet (2021-07-01). "Annual Report 2020" (PDF). Reagan-Udall Foundation . Archived (PDF) from the original on 2022-07-12. Retrieved 2022-08-05.
  209. "Member Organizations". Research!America . 2022. Archived from the original on 2022-04-06. Retrieved 2022-08-05.
  210. "Our Sponsors and Prizes". BC Pharmacy Association. 2022. Archived from the original on 2022-05-23. Retrieved 2022-08-02.
  211. "Current Sponsors". Canadian Association of Gastroenterology . 2022. Archived from the original on 2022-04-21. Retrieved 2022-08-02.
  212. "Corporate Partners". CAR - Canadian Association of Radiologists. 2022. Archived from the original on 2022-07-19. Retrieved 2022-08-02.
  213. "Corporate Sponsors - CRA". Canadian Rheumatology Association. 2017-11-18. Archived from the original on 2022-03-01. Retrieved 2022-08-02.
  214. "Home". CUA Meeting 2022. 2021. Archived from the original on 2022-05-16. Retrieved 2022-08-02.
  215. "Our Partnerships". Colorectal Cancer Canada. 2021. Archived from the original on 2022-05-16. Retrieved 2022-08-02.
  216. "Your impact". Ontario Medical Association . 2022. Archived from the original on 2022-08-05. Retrieved 2022-08-05.
  217. Hemmelgarn, Brenda R.; Clement, Fiona; Manns, Braden J.; Klarenbach, Scott; James, Matthew T.; Ravani, Pietro; Pannu, Neesh; Ahmed, Sofia B.; MacRae, Jennifer; Scott-Douglas, Nairne; Jindal, Kailash (2009-10-19). "Overview of the Alberta Kidney Disease Network". BMC Nephrology. 10 (1): 30. doi: 10.1186/1471-2369-10-30 . ISSN   1471-2369. PMC   2770500 . PMID   19840369.
  218. "Funding Partners". Can-SOLVE CKD Network. 2022. Archived from the original on 2022-08-02. Retrieved 2022-08-02.
  219. Wartell, Sarah Rosen. "2020 Annual Report" (PDF). Urban Institute . Archived (PDF) from the original on 2022-06-30. Retrieved 2022-08-05.